BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang XH, Wong BC. Cyclooxygenase-2 inhibition and gastric cancer. Curr Pharm Des. 2003;9:2281-2288. [PMID: 14529406 DOI: 10.2174/1381612033453983] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Bai X, Ding SQ, Zhang XP, Han MH, Dai DQ. Exposure to Commonly Used Drugs and the Risk of Gastric Cancer: An Umbrella Review of Meta-Analyses. Cancers (Basel) 2023;15. [PMID: 36672322 DOI: 10.3390/cancers15020372] [Reference Citation Analysis]
2 Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut 2022;71:16-24. [PMID: 34226290 DOI: 10.1136/gutjnl-2021-325097] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 25.0] [Reference Citation Analysis]
3 Abdi E, Latifi-Navid S, Abedi Sarvestani F, Esmailnejad MH. Emerging therapeutic targets for gastric cancer from a host-Helicobacter pylori interaction perspective. Expert Opin Ther Targets 2021;25:685-99. [PMID: 34410200 DOI: 10.1080/14728222.2021.1971195] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Huang XZ, Chen Y, Wu J, Zhang X, Wu CC, Zhang CY, Sun SS, Chen WJ. Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: A dose-response meta-analysis. Oncotarget 2017;8:4781-95. [PMID: 27902474 DOI: 10.18632/oncotarget.13591] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
5 Suresh A, Reddy RB, James BL, Kuriakose MA. Biological Basis of Treatment Failure. Contemporary Oral Oncology 2017. [DOI: 10.1007/978-3-319-14917-2_11] [Reference Citation Analysis]
6 Agúndez JA, Blanca M, Cornejo-garcía JA, García-martín E. Pharmacogenomics of cyclooxygenases. Pharmacogenomics 2015;16:501-22. [DOI: 10.2217/pgs.15.6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
7 Hua H, Jin C, Yang L, Tao S, Zhu X. Expression of Cyclooxygenase-2 in Squamous Cell Carcinoma and Keratoacanthoma and its Clinical Significance. Cell Biochem Biophys 2015;72:475-80. [DOI: 10.1007/s12013-014-0490-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
8 Mutoh H, Sashikawa M, Sakamoto H, Tateno T. Cyclooxygenase 2 in gastric carcinoma is expressed in doublecortin- and CaM kinase-like-1-positive tuft cells. Gut Liver 2014;8:508-18. [PMID: 25228975 DOI: 10.5009/gnl13237] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
9 Hsu KW, Wang AM, Ping YH, Huang KH, Huang TT, Lee HC, Lo SS, Chi CW, Yeh TS. Downregulation of tumor suppressor MBP-1 by microRNA-363 in gastric carcinogenesis. Carcinogenesis 2014;35:208-17. [PMID: 23975832 DOI: 10.1093/carcin/bgt285] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
10 Liao LM, Vaughan TL, Corley DA, Cook MB, Casson AG, Kamangar F, Abnet CC, Risch HA, Giffen C, Freedman ND, Chow WH, Sadeghi S, Pandeya N, Whiteman DC, Murray LJ, Bernstein L, Gammon MD, Wu AH. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 2012;142:442-452.e5; quiz e22-3. [PMID: 22108196 DOI: 10.1053/j.gastro.2011.11.019] [Cited by in Crossref: 113] [Cited by in F6Publishing: 124] [Article Influence: 10.3] [Reference Citation Analysis]
11 Park SC. Nonsteroidal Anti-inflammatory Drug Type, Frequency, and Duration of Use and Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction. Korean J Gastroenterol 2012;60:190. [DOI: 10.4166/kjg.2012.60.3.190] [Reference Citation Analysis]
12 Tseng YC, Tsai YH, Tseng MJ, Hsu KW, Yang MC, Huang KH, Li AF, Chi CW, Hsieh RH, Ku HH. Notch2-induced COX-2 expression enhancing gastric cancer progression. Mol Carcinog. 2012;51:939-951. [PMID: 21976141 DOI: 10.1002/mc.20865] [Cited by in Crossref: 35] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
13 Hsu KW, Hsieh RH, Wu CW, Chi CW, Lee YH, Kuo ML, Wu KJ, Yeh TS. MBP-1 suppresses growth and metastasis of gastric cancer cells through COX-2. Mol Biol Cell 2009;20:5127-37. [PMID: 19846662 DOI: 10.1091/mbc.e09-05-0386] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
14 Epplein M, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. Am J Epidemiol 2009;170:507-14. [PMID: 19584132 DOI: 10.1093/aje/kwp162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
15 Zhuang ZH, Tsao SW, Deng W, Wang JD, Xia HH, He H, Feng HC, Wang LD, Gu Q, Lam SK, Lin MC, Kung HF, Wong BC. Early upregulation of cyclooxygenase-2 in human papillomavirus type 16 and telomerase-induced immortalization of human esophageal epithelial cells. J Gastroenterol Hepatol 2008;23:1613-20. [PMID: 18717758 DOI: 10.1111/j.1440-1746.2008.05509.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
16 Hundahl SA, Macdonald JS, Smalley SR. Stomach. Oncology. [DOI: 10.1007/0-387-31056-8_41] [Reference Citation Analysis]
17 Al-Waili NS, Saloom KY, Al-Waili T, Al-Waili A, Al-Waili H. Modulation of prostaglandin activity, part 1: prostaglandin inhibition in the management of nonrheumatologic diseases: immunologic and hematologic aspects. Adv Ther 2007;24:189-222. [PMID: 17526477 DOI: 10.1007/BF02850008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
18 Becker J, Müller-Tidow C, Serve H, Domschke W, Pohle T. Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy. World J Gastroenterol 2006; 12(21): 3297-3305 [PMID: 16733844 DOI: 10.3748/wjg.v12.i21.3297] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 44] [Article Influence: 2.3] [Reference Citation Analysis]
19 Dai Y, Wang WH. Non-steroidal anti-inflammatory drugs in prevention of gastric cancer. World J Gastroenterol 2006; 12(18): 2884-2889 [PMID: 16718813 DOI: 10.3748/wjg.v12.i18.2884] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
20 Kim KH, Park EJ, Seo YJ, Cho HS, Kim CW, Kim KJ, Park HR. Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors. J Dermatol 2006;33:319-25. [DOI: 10.1111/j.1346-8138.2006.00076.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
21 Zhao XH, Gu SZ, Tian HG, Quan P, Pan BR. Clinical significance of expression of apoptotic signal proteins in gastric carcinoma tissue. World J Gastroenterol 2005; 11(25): 3846-3849 [PMID: 15991280 DOI: 10.3748/wjg.v11.i25.3846] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
22 Baldari CT, Lanzavecchia A, Telford JL. Immune subversion by Helicobacter pylori. Trends Immunol. 2005;26:199-207. [PMID: 15797510 DOI: 10.1016/j.it.2005.01.007] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 2.7] [Reference Citation Analysis]
23 Wu CY, Wang CJ, Tseng CC, Chen HP, Wu MS, Lin JT, Inoue H, Chen GH. Helicobacter pylori promote gastric cancer cells invasion through a NF-kB and COX-2-mediated pathway. World J Gastroenterol 2005; 11(21): 3197-3203 [PMID: 15929167 DOI: 10.3748/wjg.v11.i21.3197] [Cited by in CrossRef: 66] [Cited by in F6Publishing: 72] [Article Influence: 3.7] [Reference Citation Analysis]
24 Wang D, Mann JR, DuBois RN. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 2005;128:1445-61. [PMID: 15887126 DOI: 10.1053/j.gastro.2004.09.080] [Cited by in Crossref: 127] [Cited by in F6Publishing: 136] [Article Influence: 7.1] [Reference Citation Analysis]
25 Delvenne P, Hubert P, Jacobs N. Epithelial metaplasia: an inadequate environment for antitumour immunity? Trends in Immunology 2004;25:169-73. [DOI: 10.1016/j.it.2004.02.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
26 Lynch JP, Lichtenstein GR. Cyclooxygenase activity in gastrointestinal cancer development and progression: prospects as a therapeutic target. Cancer and Inflammation 2004. [DOI: 10.1007/978-3-0348-7861-6_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]